Charles River Laboratories International, Inc.
CRL · Price history
Price at last available close
$358.84
+$64.25 (+21.81%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Charles River Laboratories International, Inc.
Primary reporting period: 2025-12-27 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
How they make money
Charles River Laboratories provides essential products and services to pharmaceutical, biotechnology, government, and academic organizations to accelerate drug discovery and development. The company generates revenue by selling research models, providing preclinical safety assessment services, and offering laboratory support and management services, including vivarium space and staffing.
Products & services
Research models, preclinical safety assessment services, laboratory management services (CRADL), and specialized research support services for drug development.
Brands & revenue mix
Primary brand for all products and services.
Separate brand revenue is not available in this research.Source
Charles River Accelerator and Development Lab offering.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-27Source
Period ended 2025-12-27Source
Period ended 2025-12-27Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2025-12-27Source
Period ended 2025-12-27Source
Period ended 2025-12-27Source
Period ended 2025-12-27Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
The company does not disclose specific customer concentration figures in its 2025 10-K filing.
Suppliers, materials & equipment
- Non-human primate suppliers — The company sources non-human primates from audited and approved third-party suppliers for use in research and safety assessment services.Source
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-27.
Quarterly EPS turned negative at -0.03 versus 1.06 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
49
Weak
Financial Strength
56
Business Quality / Moat
73
Management
35
Growth Quality
21
Risk / Durability
43
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
23
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
32/100
Building Historical Record
Model Score 32/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •M&A headline · Aug 31, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for CRL
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving CRL's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is CRL's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is CRL's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for CRL to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CRL's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
23
Market Cap
$17.28B
P/E Ratio
-61.0
EPS
$-4.84
52-Week High
$303.31
52-Week Low
$146.20
Beta
1.41
Analyst Target
$321.00
Shares Outstanding
49.6M
Total Revenue
$4.00B
Total Debt
$3.03B
Dividend
No current dividend
Liquidation Value / Share
$57.42
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CRL
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Aug 31, 2026
Contrasting Charles River Laboratories International (NYSE:CRL) and IB Acquisition (NASDAQ:IBAC) — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on CRL.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Global infrastructure and economies of scale.
- +Controlled research model environments.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Supply chain disruptions for research models.
- −Operational risks in global infrastructure.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
7 historical score records availablePrevious Score
26
Sep 17, 2026
Change
-0.1
points
Current Score
26
Oct 1, 2026
Category Changes
CRL decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
20
Projected Change
-5.6 points
Preliminary comparable-period financial changes suggest decline of approximately 5.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$358.84
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.00B | $4.02B | $4.05B | $4.13B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $2.71B | $2.79B | $2.72B | $2.63B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $1.29B | $1.23B | $1.33B | $1.50B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $753.5M | $743.1M | $751.0M | $747.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $795.5M | $717.7M | $1.10B | $885.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $220.5M | $410.8M | $581.1M | $1.03B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $493.8M | $507.8M | $227.3M | $617.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $106.3M | $107.0M | $126.3M | $136.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$183.7M | -$99.5M | $93.1M | $581.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $52.6M | $42.7M | $67.8M | $100.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$238.5M | -$144.3M | $10.3M | $474.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-4.84 | $-2.91 | $0.20 | $9.27 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 48.49M | 49.56M | 51.38M | 51.23M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 48.49M | 49.56M | 51.63M | 51.45M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$1.00B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.03
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+8.7%
Cash Change
+5.0%
Margin Change
-5.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included revenue growth, EPS growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 2.7%. EPS declined 102.8%. Cash increased 5.0%. Total debt increased 8.7%. Net income margin declined by 5.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
32
Smart Money
32
Number of Gurus
3
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
7 historical recordsHistorical Score Chart
3 of 7 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Charles River Gains 75.8% in a Year: What's Driving the Rally?
Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Price Target of $290.00 According to Analysts
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Rumor Mill · CRL
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial